Other
Tachypnea
4
Pipeline Programs↗
1
Active Trials↗
4
Companies Involved↗
Tachypnea is an early-stage landscape with 4 programs across 4 companies. The most active players are GSK, Amphastar Pharmaceuticals, Inc., Validus Pharmaceuticals. 1 therapy is approved.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical1
Phase 2
No programs
Phase 3
No programs
Approved1
Analysis
Trial Status
4
clinical trials
Completed2 · 50%
Not yet recruiting1 · 25%
Unknown status1 · 25%
Clinical Trials
Trial Activity
Inhaled Beta-2 Agonist Versus Epinephrine For Treatment of Transient Tachypnea of Newborn (TTN)
Completed·—·Phase 1·NCT05006235·135 enrolled
Inhaled Corticosteroids for the Treatment of Transient Tachypnea of the Newborn
Unknown status·—·Phase 2·NCT01858129·56 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)